Digest Network Come funziona
Network
/
Società
Ag
Non verificato

Agendia, Inc.

Di cosa scriviamo

BiotecnologiaIndustriaOncologiaSaluteScienza

24 comunicati stampa

Guarda tutti i comunicati
26/10/2026
Scienza
Sanità
Oncologia
Vetrine/Shopping
Tecnica
Medicina - Varie
Biotecnologia
Salute
Eventi
Industria
Agendia Unveils Clinical Validation of AI-Driven Digital Pathology Approach
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
06/10/2026
Eventi
Fiere
Industria
Sanità
Scienza
Medicina nucleare
Tecnologie Varie
Oncologia
Vetrine/Shopping
Biotecnologia
Information Technology
Biologia
Tecnica
Igiene alimentare
Salute
Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 2026
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
24/09/2026
Industria
Scienza
Biotecnologia
Medicina - Varie
Sanità
Vetrine/Shopping
Salute
Oncologia
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
25/06/2026
Industria
Sanità
Scienza
Oncologia
Vetrine/Shopping
Biotecnologia
Medicina - Varie
Salute
Genomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
21/05/2026
Scienza
Biotecnologia
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
31/03/2026
Industria
Salute
Oncologia
Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
12/08/2025
Scienza
HIV, AIDS e malattie autoimmuni
Biotecnologia
Sanità
Salute
Oncologia
Analisi di mercato
Industria
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
27/05/2025
Eventi
Scienza
Biotecnologia
Medicina - Varie
Salute
Sanità
Oncologia
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO® Annual Meeting
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
15/05/2025
Eventi
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Salute
Oncologia
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025
Fonte
Agendia, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0